IDEAS home Printed from https://ideas.repec.org/a/nat/nature/v507y2014i7491d10.1038_nature12966.html
   My bibliography  Save this article

Proof of principle for epitope-focused vaccine design

Author

Listed:
  • Bruno E. Correia

    (University of Washington
    PhD Program in Computational Biology, Instituto Gulbenkian Ciência and Instituto de Tecnologia Química e Biológica, Universidade Nova de Lisboa, Oeiras 2780-157, Portugal
    The Scripps Research Institute)

  • John T. Bates

    (The Vanderbilt Vaccine Center, Vanderbilt University Medical Center)

  • Rebecca J. Loomis

    (The Children’s Hospital of Philadelphia Research Institute)

  • Gretchen Baneyx

    (University of Washington)

  • Chris Carrico

    (Fred Hutchinson Cancer Research Center)

  • Joseph G. Jardine

    (University of Washington
    The Scripps Research Institute
    IAVI Neutralizing Antibody Center, The Scripps Research Institute
    Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery, The Scripps Research Institute)

  • Peter Rupert

    (Fred Hutchinson Cancer Research Center)

  • Colin Correnti

    (Fred Hutchinson Cancer Research Center)

  • Oleksandr Kalyuzhniy

    (University of Washington
    IAVI Neutralizing Antibody Center, The Scripps Research Institute
    Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery, The Scripps Research Institute)

  • Vinayak Vittal

    (University of Washington)

  • Mary J. Connell

    (The Children’s Hospital of Philadelphia Research Institute)

  • Eric Stevens

    (University of Washington)

  • Alexandria Schroeter

    (University of Washington)

  • Man Chen

    (Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health)

  • Skye MacPherson

    (University of Washington
    The Scripps Research Institute
    IAVI Neutralizing Antibody Center, The Scripps Research Institute
    Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery, The Scripps Research Institute)

  • Andreia M. Serra

    (University of Washington
    IAVI Neutralizing Antibody Center, The Scripps Research Institute
    Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery, The Scripps Research Institute)

  • Yumiko Adachi

    (University of Washington
    IAVI Neutralizing Antibody Center, The Scripps Research Institute
    Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery, The Scripps Research Institute)

  • Margaret A. Holmes

    (Fred Hutchinson Cancer Research Center)

  • Yuxing Li

    (The Scripps Research Institute
    IAVI Neutralizing Antibody Center, The Scripps Research Institute
    Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery, The Scripps Research Institute)

  • Rachel E. Klevit

    (University of Washington)

  • Barney S. Graham

    (Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health)

  • Richard T. Wyatt

    (The Scripps Research Institute
    IAVI Neutralizing Antibody Center, The Scripps Research Institute
    Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery, The Scripps Research Institute)

  • David Baker

    (University of Washington)

  • Roland K. Strong

    (Fred Hutchinson Cancer Research Center)

  • James E. Crowe

    (The Vanderbilt Vaccine Center, Vanderbilt University Medical Center
    Microbiology and Immunology, Vanderbilt Medical Center
    Vanderbilt Medical Center)

  • Philip R. Johnson

    (The Children’s Hospital of Philadelphia Research Institute)

  • William R. Schief

    (University of Washington
    The Scripps Research Institute
    IAVI Neutralizing Antibody Center, The Scripps Research Institute
    Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery, The Scripps Research Institute)

Abstract

Vaccines prevent infectious disease largely by inducing protective neutralizing antibodies against vulnerable epitopes. Several major pathogens have resisted traditional vaccine development, although vulnerable epitopes targeted by neutralizing antibodies have been identified for several such cases. Hence, new vaccine design methods to induce epitope-specific neutralizing antibodies are needed. Here we show, with a neutralization epitope from respiratory syncytial virus, that computational protein design can generate small, thermally and conformationally stable protein scaffolds that accurately mimic the viral epitope structure and induce potent neutralizing antibodies. These scaffolds represent promising leads for the research and development of a human respiratory syncytial virus vaccine needed to protect infants, young children and the elderly. More generally, the results provide proof of principle for epitope-focused and scaffold-based vaccine design, and encourage the evaluation and further development of these strategies for a variety of other vaccine targets, including antigenically highly variable pathogens such as human immunodeficiency virus and influenza.

Suggested Citation

  • Bruno E. Correia & John T. Bates & Rebecca J. Loomis & Gretchen Baneyx & Chris Carrico & Joseph G. Jardine & Peter Rupert & Colin Correnti & Oleksandr Kalyuzhniy & Vinayak Vittal & Mary J. Connell & E, 2014. "Proof of principle for epitope-focused vaccine design," Nature, Nature, vol. 507(7491), pages 201-206, March.
  • Handle: RePEc:nat:nature:v:507:y:2014:i:7491:d:10.1038_nature12966
    DOI: 10.1038/nature12966
    as

    Download full text from publisher

    File URL: https://www.nature.com/articles/nature12966
    File Function: Abstract
    Download Restriction: Access to the full text of the articles in this series is restricted.

    File URL: https://libkey.io/10.1038/nature12966?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Eike-Christian Wamhoff & Larance Ronsard & Jared Feldman & Grant A. Knappe & Blake M. Hauser & Anna Romanov & James Brett Case & Shilpa Sanapala & Evan C. Lam & Kerri J. St. Denis & Julie Boucau & Amy, 2024. "Enhancing antibody responses by multivalent antigen display on thymus-independent DNA origami scaffolds," Nature Communications, Nature, vol. 15(1), pages 1-13, December.
    2. Namrata Anand & Raphael Eguchi & Irimpan I. Mathews & Carla P. Perez & Alexander Derry & Russ B. Altman & Po-Ssu Huang, 2022. "Protein sequence design with a learned potential," Nature Communications, Nature, vol. 13(1), pages 1-11, December.
    3. Nina G. Bozhanova & Andrew I. Flyak & Benjamin P. Brown & Stormy E. Ruiz & Jordan Salas & Semi Rho & Robin G. Bombardi & Luke Myers & Cinque Soto & Justin R. Bailey & James E. Crowe & Pamela J. Bjorkm, 2022. "Computational identification of HCV neutralizing antibodies with a common HCDR3 disulfide bond motif in the antibody repertoires of infected individuals," Nature Communications, Nature, vol. 13(1), pages 1-14, December.
    4. Yongchuan Li & Salwa Hanim Abdul-Rashid & Raja Ariffin Raja Ghazilla, 2022. "Design Methods for the Elderly in Web of Science, Scopus, and China National Knowledge Infrastructure Databases: A Scientometric Analysis in CiteSpace," Sustainability, MDPI, vol. 14(5), pages 1-18, February.
    5. Robert J. Ragotte & David Pulido & Amelia M. Lias & Doris Quinkert & Daniel G. W. Alanine & Abhishek Jamwal & Hannah Davies & Adéla Nacer & Edward D. Lowe & Geoffrey W. Grime & Joseph J. Illingworth &, 2022. "Heterotypic interactions drive antibody synergy against a malaria vaccine candidate," Nature Communications, Nature, vol. 13(1), pages 1-12, December.
    6. Ian A. Durie & Zahra R. Tehrani & Elif Karaaslan & Teresa E. Sorvillo & Jack McGuire & Joseph W. Golden & Stephen R. Welch & Markus H. Kainulainen & Jessica R. Harmon & Jarrod J. Mousa & David Gonzale, 2022. "Structural characterization of protective non-neutralizing antibodies targeting Crimean-Congo hemorrhagic fever virus," Nature Communications, Nature, vol. 13(1), pages 1-12, December.
    7. A. Brenda Kapingidza & Daniel J. Marston & Caitlin Harris & Daniel Wrapp & Kaitlyn Winters & Dieter Mielke & Lu Xiaozhi & Qi Yin & Andrew Foulger & Rob Parks & Maggie Barr & Amanda Newman & Alexandra , 2023. "Engineered immunogens to elicit antibodies against conserved coronavirus epitopes," Nature Communications, Nature, vol. 14(1), pages 1-18, December.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:nature:v:507:y:2014:i:7491:d:10.1038_nature12966. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.